InvestSMART

Nova Eye Medical Limited (ASX:EYE)

ALERT: Price-sensitive ASX Announcement for EYE
Current share price for EYE : $0.110 -0.05 (-31.25%)+
Announcement
Release
26 Feb 2026 8:15AM
Price at Release
$0.160
Full Release
download
Summary
Nova Eye Medical Limited's half-year report ending 31 December 2025 indicates a significant financial improvement compared to the previous period. The company recorded a lower group loss after tax of $3,365,000, improved EBITDA-level loss, and a revenue increase by 29%. This financial turnaround is attributed to a higher gross margin of 70% and operational efficiency. However, operating expenses rose due to increased sales commissions and investment in various operational areas. The company, focusing on two main segments, continues to strategize its financial planning to ensure sustainability, with no impairments recorded for its Glaucoma Surgical Devices segment.
Key Points
  • Nova Eye Medical Limited recorded a group loss after tax of $3,365,000 for the six months ended 31 December 2025.
  • The EBITDA-level loss was $2,204,000, showing an improvement from the previous year's loss.
  • Revenue grew by 29% to $16,712,000 compared to the previous period.
  • Gross margin improved to 70%, driven by production efficiency and pricing discipline.
  • Operating expenses increased due to higher variable sales commissions and investments in clinical data and regulatory activities.
  • The company has considered various financial strategies to ensure its continuation as a going concern.
  • Nova Eye Medical Limited operates in two business segments: AlphaRET and Glaucoma Surgical Devices.
  • The report highlights no impairment losses for the Glaucoma Surgical Devices segment as of 31 December 2025.
  • No significant events occurred after the interim period that would affect the company’s operations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.